Krystal J H, Webb E, Cooney N, Kranzler H R, Charney D S
Department of Psychiatry, Veterans Affairs-Yale Alcoholism Research Center, Yale University School of Medicine, West Haven, Conn.
Arch Gen Psychiatry. 1994 Nov;51(11):898-911. doi: 10.1001/archpsyc.1994.03950110058008.
This study evaluated the specificity of the ethanollike effects of the serotonergic receptor partial agonist m-chlorophenylpiperazine hydrochloride (MCPP) relative to the alpha 2-adrenergic receptor antagonist yohimbine hydrochloride and the placebo in recently detoxified alcoholics. It also examined the relationship between ethanollike discriminative properties and the induction of craving in these patients. Both MCPP and yohimbine are anxiogenic in humans; thus, this study evaluated the role of anxiogenic and ethanollike effects in the elicitation of craving.
Twenty-two male inpatients who met DSM-III-R criteria for alcohol dependence and who had not consumed alcohol for 12 to 26 days prior to the study completed 3 days of testing that involved the intravenous infusion of MCPP (0.1 mg/kg), (0.1 mg/kg), yohimbine hydrochloride (0.4 mg/kg), or a saline solution over 2 weeks under double-blind conditions. Ethanollike subjective effects were assessed using the Sensation Scale and visual analog scales to measure the degree of similarity to the effects of ethanol, cocaine, and marijuana. Five components of craving for alcohol were assessed using visual analog scales. The effects of the drugs on mood were assessed using visual analog scales. Plasma levels of cortisol, prolactin, and 3-methoxy-4-hydroxyphenylethyleneglycol were also measured during the test days.
m-Chlorophenylpiperazine and yohimbine produced significant increases compared with placebo in Sensation Scale scores and the visual analog scale score for nervousness. However, the effects of MCPP were rated as more similar to those of ethanol, cocaine, and marijuana than were those of either yohimbine or placebo. Also, MCPP but not yohimbine or placebo significantly increased craving for alcohol. Yohimbine and MCPP increased plasma prolactin and cortisol levels relative to placebo, whereas only yohimbine increased plasma 3-methoxy-4-hydroxyphenylethleneglycol levels.
m-Chlorophenylpiperazine produced ethanollike effects and alcohol craving in recently detoxified alcoholics. Yohimbine increased Sensation Scale scores but was not recognized as ethanollike by patients. Although both drugs produced comparable levels of nervousness, yohimbine did not increase craving for alcohol. These data further implicate serotonergic systems in the discriminative properties of ethanol and may indicate a serotonergic contribution to craving. Noradrenergic systems contributed to the discriminative properties of ethanol but not to those features of ethanol response that were salient to craving in this population.
本研究评估了血清素能受体部分激动剂盐酸间氯苯哌嗪(MCPP)相对于α2 - 肾上腺素能受体拮抗剂盐酸育亨宾及安慰剂,对近期戒酒的酗酒者产生类似乙醇效应的特异性。该研究还检测了这些患者中类似乙醇的辨别特性与渴求感诱导之间的关系。MCPP和育亨宾在人类中均具有致焦虑作用;因此,本研究评估了致焦虑作用和类似乙醇效应在诱发渴求感中的作用。
22名符合DSM - III - R酒精依赖标准且在研究前12至26天未饮酒的男性住院患者,在双盲条件下,于2周内完成了为期3天的测试,测试过程中静脉输注MCPP(0.1mg/kg)、育亨宾(0.4mg/kg)或生理盐水。使用感觉量表和视觉模拟量表评估类似乙醇的主观效应,以测量与乙醇、可卡因和大麻效应的相似程度。使用视觉模拟量表评估对酒精渴求的五个组成部分。使用视觉模拟量表评估药物对情绪的影响。在测试日还测量了血浆皮质醇、催乳素和3 - 甲氧基 - 4 - 羟基苯乙二醇的水平。
与安慰剂相比,MCPP和育亨宾使感觉量表得分以及紧张程度的视觉模拟量表得分显著增加。然而,与育亨宾或安慰剂相比,MCPP的效应被评定为与乙醇、可卡因和大麻的效应更相似。此外,MCPP显著增加了对酒精的渴求,而育亨宾和安慰剂则未。相对于安慰剂,育亨宾和MCPP增加了血浆催乳素和皮质醇水平,而只有育亨宾增加了血浆3 - 甲氧基 - 4 - 羟基苯乙二醇水平。
MCPP在近期戒酒的酗酒者中产生了类似乙醇的效应和对酒精的渴求。育亨宾增加了感觉量表得分,但患者未将其识别为类似乙醇的效应。尽管两种药物产生了相当程度的紧张感,但育亨宾并未增加对酒精的渴求。这些数据进一步表明血清素能系统参与了乙醇的辨别特性,并且可能表明血清素能系统对渴求感有影响。去甲肾上腺素能系统参与了乙醇的辨别特性,但对该人群中与渴求感相关的乙醇反应特征没有影响。